A curated database of drugs, molecules, targets, trials, Medicare & Medicaid spending and patents — queried in plain English by a research assistant built for diligence.
| MOLECULE | SPEND 23 | LOE | 3Y TREND |
|---|---|---|---|
| IBRUTINIB | $2.41B | 2026 | |
| ABIRATERONE | $1.88B | 2025 | |
| PALBOCICLIB | $1.52B | 2027 | |
| ENZALUTAMIDE | $1.34B | 2027 |
Patent cliffs, exclusivity windows and generic entry across the molecule portfolio.
Medicare & Medicaid spend, volume and reimbursement trends by drug, class and region.
Phase, sponsor, endpoint and enrolment across the active and historical trial record.
Map molecules to biological targets, mechanisms of action and competing programs.
Patent families, expiries and litigation tied to each asset and its formulations.
Every answer is traceable to the underlying record — sources you can take to committee.